|| Checking for direct PDF access through Ovid
Until recently, pharmacological studies dealing with vasopressin receptor isoforms were severely hampered by the lack of selective agonists or antagonists that recognize the pituitary V1b vasopressin receptor. By contrast, many selective vasopressin-related compounds are available for characterization of the vasopressor (V1a) or antidiuretic (V2) vasopressin receptor subtypes. Recently, SSR149415, a selective nonpeptide molecule, was discovered with nanomolar affinity for mammalian V1b receptors and good selectivity for the other vasopressin and oxytocin receptor isoforms. This molecule exhibits potent antagonist properties both in vitro and in vivo. We also designed synthetic peptides derived from [deaminocysteine1,arginine8]vasopressin (dAVP), modified in position 4 by various amino acid residues. Some of these, d[cyclohexylalanine4]AVP or d[lysine4]AVP, have a high affinity and an excellent selectivity for the human V1b receptor subtype. However, they exhibit a mixed V1b/V2 pharmacological profile for the rat vasopressin receptor isoforms. Whatever the species considered, these peptides behave as agonists both in bioassays performed in vitro and in vivo. The d[cyclohexylalanine4]AVP was tritiated and represents the first selective radiolabelled ligand available for studying the human V1b receptors. The discovery of these new selective V1b agonists and V1b antagonist allows an accurate pharmacological characterization of all the vasopressin receptor isoforms. As emphasized in this review, attention to the vasopressin and oxytocin receptor species differences is of critical importance in studies with all vasopressin and oxytocin ligands.